Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.53

+4.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1132)	5/29/2000 4:01:00 PM
From: tuck	Read Replies (1) of 52153

Peter, Hoping you folks get MedScape. If not you can register for free. "Because of this finding, the vast literature on chemotherapy response rates for advanced breast cancer is more or less obsolete . . ." This comment by Dr. Harold Bluestein may be one example of why we didn't get a boost from ASCO. To find out why he said that, go to medscape.com I'd be curious to hear y'all's take on this. Does this mean a whole bunch of clinical trials involving advanced breast cancer are essentially invalid? That companies will have to redisgn and redo trials in this area? Or am I reading too much into it? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next